MedTrace Logo

Biomarker for Alport Syndrome (BioAlport)

NCT02718027 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2023-02-10

No results posted yet for this study

Summary

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Conditions

  • Nephritis, Hereditary
  • Hematuria-Nephropathy-Deafness Syndrome

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. Dr. · Centogene GmbH

Eligibility

Min Age
2 Months
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Albania
  • Georgia
  • India
  • Lithuania
  • Pakistan
  • Romania
  • Sri Lanka

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718027 on ClinicalTrials.gov